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Abstract: Quality Control for Molecular Diagnostics (QCMD), an international provider for External
Quality Assessment (EQA) programmes, has introduced a programme for molecular diagnostics
of Zika virus (ZIKV) in 2016, which has been continuously offered to interested laboratories
since that time. The EQA schemes provided from 2016 to 2018 revealed that 86.7% (92/106),
82.4% (89/108), and 88.2% (90/102) of the participating laboratories reported correct results for all
samples, respectively in 2016, 2017, and 2018. The review of results indicated a need for improvement
concerning analytical sensitivity and specificity of the test methods. Comparison with the outcomes
of other EQA initiatives briefly summarized here show that continuous quality assurance is important
to improve laboratory performance and to increase preparedness with reliable diagnostic assays for
effective patient management, infection and outbreak control.
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1. Introduction
Zika virus (ZIKV) is a mosquito-borne flavivirus which had been considered to have low
pathogenicity, with only very sporadic human cases and outbreaks reported in the past [1]. In 2015,
ZIKV was first detected in patients in Brazil, which was a viral strain of the Asian lineage [2,3].
After introduction into South America, the virus has spread rapidly in over 48 countries and territories
in the Americas, with over 220,000 confirmed autochthonous cases and over 3500 confirmed congenital
cases associated with ZIKV infection [4]. During this rapid emergence, the World Health Organization
(WHO) declared a Public Health Emergency of International Concern (PHEIC) in response to a cluster
of microcephaly cases among newborns and other neurological disorders, like Guillain-Barré syndrome,
in adults [5]. In accordance with the situation, the WHO assigned the development, assessment and
validation of ZIKV diagnostic assays as a priority [6]. The PHEIC declaration ended in November
2016 with a longer-term programmatic approach for control and prevention [7].
Laboratory preparedness with access to reliable diagnostic assays, when facing an outbreak of
arboviral infections and increase of international travel, is a key issue for patient management, infection
and outbreak control worldwide [8–13]. Since the beginning of the ZIKV outbreak many diagnostic
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tests, mostly molecular in-house assays, have been developed [6,14–16]. Molecular methods are
preferred for laboratory diagnosis of acute cases, especially in the early stage of arboviral infection [17].
Specific assays have been published for Asian and African ZIKV strains targeting several genomic
regions including the envelope and NS5 [14,15,17]. Several months after the initial outbreak, there are
also some commercial molecular assays available for ZIKV genome detection which have received
regulatory approval [6,18,19].
Quality Control for Molecular Diagnostics (QCMD) is an international provider for External
Quality Assessment (EQA) programmes covering a comprehensive range of infectious diseases [20].
The aims of QCMD’s EQA programmes are to help monitor and improve laboratory quality by
assessing a laboratory’s use of molecular diagnostic technologies within the routine clinical setting.
Participation in EQA programmes is a requirement for achieving accreditation/certification according
to the International Organization for Standardization (ISO) 15189 (‘Medical laboratories–requirements
for quality and competence’ [21]) or equivalent regulatory requirements. After the declaration of the
PHEIC related to ZIKV in February 2016, QCMD rapidly introduced an EQA programme for molecular
diagnostics of ZIKV in August 2016 to support the laboratory’s requirements and provide appropriate
proficiency testing options from then on. Here we review the results of the EQA schemes performed
from 2016 to 2018 showing need for improvement concerning analytical sensitivity and specificity of
the test methods.
2. The QCMD Zika Virus EQA Programme, 2016–2018
QCMD distributes the EQA programme for molecular diagnostics of ZIKV to registered
laboratories annually. The annual EQA schemes have different panel compositions comprising
eight to 12 lyophilized samples with samples containing cell culture-derived, inactivated African-
and Asian-lineage ZIKV at different concentrations, specificity controls covering a range of related
flaviviruses and other arboviruses, and negative samples with transport medium only. Furthermore,
each QCMD panel includes the first WHO international standard (IS) for ZIKV for molecular assays,
developed by the Paul-Ehrlich-Institut (PEI code number 11468/16 [22]) which allows traceability
of EQA materials and comparability of laboratory performance in order to resolve the lack of assay
standardization [23]. This material was officially established as WHO IS by the WHO Expert Committee
on Biological Standardization in October 2016, however the candidate material had been made available
prior to its establishment as the WHO IS for proficiency testing, assay development and clinical use
because of the urgent need for quality-assured diagnostics [6].
All EQA programme and panel design specifications are defined by QCMD in close collaboration
with Scientific Experts in the field, based on epidemiological, clinical and/or technical aspects.
Participating laboratories are expected to test each panel using their routine molecular assays and
workflows, and to report their results together with information of the applied extraction and
amplification methods through the online reporting system to QCMD [20].
The panel compositions and performances for 2016–2018 are shown in Table 1. Participation
has been relatively high since the introduction of the EQA programme, with 106 (116 datasets),
108 (114 datasets), and 102 (112 datasets) participating laboratories from around 37 countries
worldwide, including those in affected geographical regions (with up to 17% of participating
laboratories from affected countries like Brazil, Mexico, Panama), respectively, in 2016, 2017 and
2018. The results were predominantly generated by commercial assays with 54.3% (2016), 57.0% (2017),
and 52.7% (2018) of the submitted datasets. No remarkable difference in performance between in-house
and commercial assays were observed, however for some specific commercial assays analytical
challenges could be identified concerning sensitivity with lower sample concentrations as well
as specificity issues producing false positive results (data not specified). Please note that these
observations do not allow a solid and statistically assured statement as EQA studies per se are not
appropriate for assay validation.
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Table 1. Quality Control for Molecular Diagnostics (QCMD) Zika Virus External Quality Assessment (EQA) Programme. Panel compositions and
performances, 2016–2018.
(A) Data and Results on the Individual EQA Sample Level
EQA Scheme 2016 EQA Scheme 2017 EQA Scheme 2018



















ZIKV MR766 4.7 ZIKA16-08 97.4 116 ZIKA17S-07 97.4 114 ZIKA18S-05 97.3 112
ZIKV MR766 4.7 ZIKA16-09 99.1 116 - - - - - -
ZIKV MR766 3.7 ZIKA16-10 95.7 116 ZIKA17S-06 95.6 114 ZIKA18S-04 95.5 112
ZIKV MR766 2.7 ZIKA16-02 93.1 116 ZIKA17S-03 89.5 114 ZIKA18S-06 89.3 112
ZIKV 11474/16 5.7 ZIKA16-04 100 116 - - - - - -
ZIKV 11474/16 3.7 - - - ZIKA17S-01 94.7 114 ZIKA18S-01 93.8 112
ZIKV 11468/16 5.7 ZIKA16-06 100 116 - - - - - -
ZIKV 11468/16 4.7 ZIKA16-03 100 116 ZIKA17S-05 99.1 114 ZIKA18S-03 97.3 112
ZIKV 11468/16 3.7 - - - ZIKA17S-04 96.5 114 ZIKA18S-02 94.6 112
Non-Zika flaviviruses - ZIKA16-01 94.8 116 ZIKA17S-02 98.2 114 ZIKA18S-07 98.2 112
Chikungunya virus - ZIKA16-07 96.6 116 - - - - - -
Transport medium - ZIKA16-05 97.4 116 ZIKA17S-08 96.5 114 ZIKA18S-08 100 112



























Positive samples contained different concentrations of Zika virus strain Uganda MR766 provided by the Robert Koch-Institut (RKI) (representing the African lineage), ZIKV reference
material 11474/16 prepared by the Paul-Ehrlich-Institut (PEI) (from French Polynesian ZIKV strain PF13/251013-18, representing the Asian lineage), or WHO IS preparation 11468/16
developed by PEI (from French Polynesian ZIKV strain PF13/251013-18, representing the Asian lineage) [24,25]. Negative samples contained a mixed sample of flaviviruses other than
ZIKV (dengue virus serotype 2, DENV-2; West Nile virus strain NY99, WNV-NY99 and yellow fever virus 17D, YFV-17D) and/or a sample with chikungunya virus (CHIKV) for specificity
control, and a sample with transport medium only (which was used as sample matrix for the EQA samples). All cell culture-derived arboviral samples were inactivated and lyophilized.
# A dataset is defined as one qualitative laboratory result per sample and applied workflow.
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In the EQA schemes of 2016–2018, all samples were designated by the QCMD Scientific Experts as
Core proficiency samples, which are expected to be correctly reported by the participating laboratories
within the EQA challenge in order to show an acceptable level of proficiency/successful participation.
The percentage of datasets with All Core samples correctly reported were 86.2% (2016), 82.5% (2017),
and 85.7% (2018) (see Table 1). At the laboratory level, these were 86.7% (92/106), 82.4% (89/108),
and 88.2% (90/102), respectively. Incorrect results (including false positive or not determined) were
reported for the true negative sample containing transport medium only (2.6% in 2016; 3.5% in 2017;
0.0% in 2018), for a specificity negative sample containing a mixture of flaviviruses other than ZIKV
(5.2% in 2016; 1.8% in 2017; 1.8% in 2018), and for a specificity negative sample containing chikungunya
virus (3.4%, only included in 2016).
Review of the three QCMD EQA schemes performed between 2016 and 2018 demonstrate that the
overall qualitative performance of participating laboratories for molecular diagnostics of ZIKV was at
an acceptable level. However, analytical sensitivity and specificity remain a challenge. False positive
results may lead to misdiagnosis and potentially affect clinical decisions. Processes should be reviewed
by laboratories reporting false positive results. The risk of a false negative result was a concern for
a small number of laboratories and may result in failure to detect a ZIKV in low concentration in
infected patients during the acute phase of the disease. Laboratories who were unable to detect the
lower concentrated samples should strive to improve the sensitivity of the ZIKV molecular assay used.
3. Review of Results from Other EQA Initiatives
To date, a further three EQA activities for ZIKV molecular diagnostics performed by different
groups have been identified showing similar observations as mentioned above [26–28].
Fischer et al. [26] conducted an EQA study for Brazilian laboratories in 2017. Fifteen laboratories
participated in this study applying their routine molecular diagnostics for ZIKV on a panel comprising
12 lyophilized samples with inactivated full virus spiked into arbovirus-negative human plasma.
The panel included four ZIKV-positive samples with 103–106 RNA copies/mL (representing the
African and Asian lineage, including the outbreak strain in the Americas) to assess sensitivity, seven
different arbovirus-positive samples (chikungunya virus, CHIKV; dengue viruses, DENV-2 & DENV-4;
Japanese encephalitis virus, JEV; St. Louis encephalitis virus, SLEV; West Nile virus, WNV; yellow
fever virus, YFV) for specificity control, and a negative plasma sample. In addition, the WHO IS [24]
as well as a ZIKV armored RNA standard available at the EVAg portal (European Virus Archive goes
Global) were provided as references for quantification of the ZIKV-positive samples. Only 27.0% (four
of 15 laboratories) reported correct results for all samples, while 73.0% (11/15) had limited sensitivity
(correctly testing only the two samples with the highest ZIKV concentration) and/or specificity
(including false positive results from ZIKV-negative samples).
Abdad et al. [27] pointed out how important it is to continually offer and expand an EQA
initiative for emerging arboviruses which helps to assess the laboratory performance and to increase
the preparedness in a certain region. The WHO Regional Office for the Western Pacific Region (WPR)
started with an EQA pilot for two participating laboratories in 2011, including only dengue virus,
and developed it to a global EQA programme for arbovirus diagnostics (including CHIKV, DENV, YFV,
and ZIKV) with participation of 96 laboratories worldwide (of which 25 were coming from 19 countries
in the WPR) in 2016. In 2016, the panels contained blinded samples with different concentrations
for the four targeted arboviruses and were shipped to the participants between November and
December. For ZIKV, 72.0% (18 of 25 laboratories of the WPR) reported correct results in all samples,
while 28.0% (seven) had at least one false result which was not further specified.
Charrel et al. [28] published an EQA study that was performed by the Emerging Viral Diseases
Expert Laboratory Network (EVD-LabNet, Rotterdam, The Netherlands) in October/November 2016 to
assess and to improve the capability of European reference and expert laboratories for ZIKV molecular
detection. Fifty laboratories (reporting 85 datasets) from 31 countries took part in this study, using
mostly in-house assays (72.0% of the submitted datasets). The panel consisted of 12 lyophilized
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samples with inactivated virus spiked into plasma or urine, including six ZIKV-positive samples with
103–109 copies/mL (representing the African and Asian lineage, including the outbreak strain in the
Americas; calibrated using in vitro-transcribed ZIKV RNA), three different arbovirus-positive samples
(CHIKV, YFV, DENV-1), and three negative plasma or urine samples. Based on the submitted results, all
samples were assigned as core samples, having a ZIKV status scored correctly by >50% of the participating
laboratories. The study revealed that only 40.0% of the laboratories (20/50), representing 45.0% of the
countries, achieved a sufficient analytical performance. 60.0% of the laboratories (30/50) had a need to
improve their molecular ZIKV detection in relation with specificity, but more obviously with sensitivity
as only half of the laboratories correctly scored the sample with the lowest concentration.
4. Conclusions
Although the comparison of the recent results from the QCMD Zika Virus EQA Programme done
for 2016–2018 with the briefly summarized outcomes of the other EQA initiatives for ZIKV molecular
diagnostics shows great variations in laboratory performance with 27.0–88.2% of participating
laboratories reporting correct results for all samples, all EQAs indicate that there is a clear need
to improve sensitivity and specificity of ZIKV molecular assays.
The ZIKV molecular diagnostics would benefit greatly from the use of standards and controls
in order to ensure that laboratories would also detect lower viral loads as known from the
literature [17,29,30] to avoid false negative results during acute infection. The continued use of the
WHO IS as included in the QCMD EQA programme for molecular diagnostics of ZIKV will help to
support assay standardization and to improve quality performance of molecular ZIKV diagnostics.
As ZIKV and other arboviruses (e.g., DENV, CHIKV) co-circulate affecting many endemic
countries and at-risk countries globally, being a risk for local populations and international travelers,
it is important that laboratories can accurately detect and differentiate to avoid false positive results,
potentially having serious consequences for patients as exemplified by a dramatic increase in
abortion requests in South America during the 2016 ZIKV outbreak [31]. Regular participation
in EQA schemes by laboratories is important to monitor the improvement in laboratory performance;
also, for laboratories outside endemic regions a regular EQA participation would provide confidence
in tests when positive samples are not routinely seen.
Laboratories should be aware of the limitation of their assays and perform their own validation
and verification in line with ISO 15189 and other requirements. Continually offered EQA programmes
for arbovirus diagnostics are an important tool to improve laboratory performance and to increase
preparedness having quality-assured assays disponible for effective patient management, infection
and outbreak control.
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